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of about 5 to 38 mm to the plus direction in the range of 60 to 330 
degrees of the maximum dose and 100% of the isodose lines(Fig.1). On 
the other hand, a range of about 310 degrees in 97%, 95% and 93% of 
the isodose lines showed the value of about 10mm to a plus direction. 
The extended DTA for 97% to 80% of the isodose lines showed a value 
of 1 mm to the plus direction at 270 degrees (the rectum side). 
Although the extended DTA showed a large value (maximum dose and 
100% of the isodose lines), this was considered a cause for concern, 
because the dose slope was small and the interval of the isodose lines 
was small. The pass rate of the gamma values is 98.8%. Therefore, a 
clear error was undetectable. Therefore, gamma analysis and DTA are 
both useful tools, but they do not allow to evaluate the displacement 
direction of isodose lines in the arbitrary position on dose distribution. 
On the other hand, the extended DTA includes a 2D position and a 
direction for the dose difference, so it was able to detect the risk of 
overdose and under-dosefor the target and OAR. 
 
 
Conclusions: This study proposes a novel method—extended DTA—that 
incorporates the concept of displacement direction in DTA and might 
be an effective method for evaluating dose differences and directions 
in radiotherapy.  
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Purpose/Objective: To compare the secondary radiation doses 
following intensity-modulated radiotherapy (IMRT), Rapidarc and 
Tomotherapy(TOMO) in patients with lung cancer by using a 
radiophotoluminescence glass dosimeter (RPLGD) which is newly 
introduced, as a substitution of themoluminescence dosimeter (TLD) 
or other. 
Materials and Methods: Patient data and treatment planning. We 
randomly selected five patients with lung cancer who were to be 
treated with IMRT at our institution. All of these patients had 
undergone treatment planning CT scans (Brilliance CT Big Bore 
Oncology; Philips Medical System, The Netherlands) of the chest for 
identification of targets and normal neighboring organs. An Eclipse 
(Varian Medical Systems, Palo Alto, CA, USA) and Hi-Art 
(TomoTherapy, Madison, WI, USA) planning system were used to plan 
IMRT, Rapidarc and TOMO for five patients. The patient group is 
consists of three male and two female patient. The range of age is 
from 56 to 71 years old as average age of 67. All patients are stage III 
of non small cell lung cancer (NSCLC) cases and PTV volumes are 
varied from 210 to 890 cc. Measurement of secondary dose during 
IMRT, VMAT and Tomotherapy treatment. Secondary radiation was 
assessed by measuring the ionization of the photon beam (6MV) as a 
function of distance from the iso-center. These measurements were 
performed using two RPLGDs set at distances 20, 35, 50, 65 and 80 cm 
from the beam iso-center on a solid phantom. Secondary photon doses 
were measured using a RPLGD on the surface of couch table; thus, the 
secondary dose, measured at various distances from the isocenter, 
was the maximum possible dose at that distance and decreased with 
depth in the body. Therefore, the actual doses at certain body depths 
at each distance from the iso-center will be smaller than the 
measured doses. 
Results: The secondary dose per Gy (i.e., a treatment dose of 1 Gy) 
from IMRT for lung cancer, measured at 20 to 80 cm from the iso-
center ranged from 0 to 4 cGy which is higher when the PTV volume is 
large or measuring point closed to field edge. The secondary dose per 
Gy from RapidArc and TOMO ranged from 0 to 2 cGy and from 0 to 1 
cGy, respectively. It is indicating that TOMO is associated with a 
relatively small dose of secondary radiation than IMRT and RapidArc 
when the measuring point is around the field edge in spite of that 
tomotherapy has more than approximately 5 times lager monitor units 
than the other. In addition, RapidArc gives approximately 70% of 
monitor unit (MU) per fraction comparing to IMRT, indicating that 
RapidArc is associated with a smaller MU and short treatment time 
than other techniques. 
Conclusions: In conclusion, the secondary dose from TOMO is less than 
the secondary dose from conventional IMRT and RapidArc around the 
target area in spite of that tomotherapy has relatively higher monitor 
units(mu) than the other modalities. In another hand, it is found that 
rapidarc has shorter treatment time and MU than IMRT and TOMO. 
   
EP-1151   
A GEM detector for the 2D dosimetry in modern radiotherapy 
treatment verification 
G. Claps1, M.D. Falco2, F. Murtas1, R. Santoni2 
1Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali di 
Frascati, Frascati (Roma), Italy  
2Tor Vergata University General Hospital, Department of Diagnostic 
Imaging Molecular Imaging Interventional Radiology and 
Radiotherapy, Rome, Italy  
 
Purpose/Objective: Intensity-modulated radiotherapy treatment is 
the most advanced technique for external beam photon radiotherapy. 
It allows todeliver a highly conformal dose to the patients. However, 
if on one hand the accelerator machine and the elaborate software 
dedicated to it allow to achieve such performances, on the other the 
problem of how to verify that the doses are irradiated within the 
planned limits of compatibility remains unsolved, because it demands 
stringent quality assurance. Generally 3D dose distributions obtained 
from a treatment planning system have to be verified by dosimetric 
methods. Usually, a comparison of two-dimensional calculated and 
measured data in several coplanar planes is performed. We propose 
the application of a GEM (Gas Electron Multiplier) detector. The 
particular configuration designed at the Frascati National Laboratories 
shows interesting properties which may overcome the limitations of 
conventional systems: low spatial resolution (> 2 mm), dose rate 
dependence, limited linearity, long acquisition times. 
Materials and Methods: Our GEM detector is a gas detector working as 
proportional counter. Gas mixture used is ArCO2 (70/30). The 
multiplication stages are made of three GEM foil. A GEM is made of at 
thin (50 μm) kapton foil, a copper cladding on each side, perforated 
with a high surface density of holes,each one acting as an electron 
multiplication channel. Each hole has a bi-conical structure with 
external (internal) diameter of 70 μm (50 μm) and a pitch of 140 μm. 
The detector has an anode consisting of 128 pads in a row. Each pad 
has an area of 0.5x0.5 mm, so that we can measure with a spatial 
resolution of 0.7 mm, which is the pitch between two successive pads. 
Moreover, equipping the detector of a linear motion system, we can 
obtain a dose measurement on a matrix of 128 x 128 points. Signals 
from the pad are digitalized and transferred through an ethernet 
cable on a PC, where they can be can be displayed and recorded. We 
performed a series of 2D dose measurements on the Eleckta Synergy 
clianical accelerator located in the Radiotherapy Department of the 
Tor Vergata University General Hospital. At the moment, our detector 
has an area of 10x10 cm, so we tested it on small fields. Data were 
acquired with the detector at the isocenter position (100 cm from the 
souce).  
Results: Results obtained show that our detector can measure very 
rapidly small X-ray dose fields with the resolution we expected. A 
single 1D beam profile can be taken in times minor than 100 ms. 
Moreover it shows an excellent linearity on dose rates ranging from 6 
to 400 MU/min. This has allowed us to have a dose measurement in a 
very wide range of values. 
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Previous images show the 2D dose maps obtained with the GEM 
detector in 64 seconds. On the right there is the map for a 2,4 x 2,4 
cm X-rays irradiation field, on the left the one for a 4,0 x 4,0 cm X-
rays irradiation field. 
Conclusions: Our detector could represent significant improvement 
compared to measurement systems used until today. The results 
confirm its potentialities especially in terms of spatial resolution, 
acquisition time and linearity.  
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Purpose/Objective: Two-dimensional (2D) array detector has finite 
resolution due to its detector size and spacing. Dosimetric verification 
of small targets planned with IMRT is difficult because of the limited 
resolution as only a limited number of pixels handling the fluence. In 
addition, the overall inaccuracy due to the interpolation of signals will 
be higher. However, if the small field IMRT is verified at extended 
source to surface distance (SSD), fluence can be handled by the large 
area of the array and hence the more number of detectors due to 
inverse square law. Therefore, the purpose of the present study is to 
evaluate the response of 2D-detector array at extended SSDs for pre-
treatment verification of small targets. 
Materials and Methods: Four previously treated patients were 
studied. In planning CT slices, planning target volume (PTV) and organ 
at risk (OAR) were contoured. IMRT (sliding window) plans were 
generated in Eclipse (Varian Medical Systems, Palo Alto, CA, USA) 
treatment planning system (TPS) for Varian CL2300C/D linear 
accelerator using 5-7 fields of 6MV photon beam. For each patient, 
four verification plans were generated at 95cm, 100cm, 105cm and 
110cm SSD by keeping I’matriXX at 5cm depth. The planned fluence 
was then transferred to previously scanned I’matriXX (IBADosimetry, 
Scanditronix Wellhofer, Germany) and solid water slab assembly and 
doses were calculated. The dose planes measured with I’matriXX were 
compared with TPS calculated dose planes at corresponding SSD in 
OmniPro-IMRT software using 2D gamma (γ) index analysis. For gamma 
index analysis, 3% dose difference and 3mm distance to agreement 
criteria (3%/3mm) was used. Three parameters i.e. gamma maximum 
(γmax.), gamma average (γavg.)and percentage of pixels passing gamma 
value up to 1 (γ% ≤1) were noted. 
Results: 
Results are summarized in table-1. 
 
Table-1 shows the γ index analysis results for four patients 
 
 
 Patient-1 Patient-2 
SSD (cm) 95 100 105 110 95 100 105 110 
γ% ≤1 99.73 99.92 99.98 99.97 99.84 99.93 99.85 99.94 
γmax. 1.57 1.25 1.14 1.18 1.47 1.33 1.42 1.36 
γavg. 0.07 0.07 0.08 0.09 0.03 0.03 0.04 0.04 
 Patient-3 Patient-4 
SSD (cm) 95 100 105 110 95 100 105 110 
γ%≤1 99.25 99.63 99.48 99.58 99.55 99.78 99.90 99.87 
γmax. 1.68 1.51 1.61 1.73 1.95 1.77 1.37 1.48 
γavg. 0.08 0.07 0.08 0.07 0.05 0.05 0.05 0.06 
 
Figure-1 shows the increase in measurement area with increase in SSD 
from 95-110cm 
 
 
Conclusions: The verification of small IMRT fields showed increased 
gamma pass rate when measured at extended SSDs compared to the 
verification at normal measurement distance. This may be attributed 
to the involvement of increased number pixel chambers at larger SSD 
which increased the resolution and accuracy of measured dose-plane.  
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Purpose/Objective: To investigate the properties and efficacy of 
ArcCHECK (Sun Nuclear Corp., Melbourne, FL) in quality assurance 
(QA) of Helical TomoTherapy treatment delivery. 
Materials and Methods: Nine clinical Helical TomoTherapy plans of 
different treatment regions and beam widths were randomly selected 
for dosimetric QA measurement using ArcCHECK. A series of test plans 
with cylindrical targets of different dimensions and with different 
treatment beam widths were also made for testing the performance 
of ArcCHECK. Fine grid was used for all test plan optimisation and 
dose calculation. Gamma analysis (passing criteria: 3 % dose 
